Exelixis, Inc.
Exelixis, Inc. (EXEL) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · EXEL · as of Jun 8, 2026
Key Statistics
Explore Exelixis, Inc. Data
exel stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 32 · Buy rate: 50.0%
The EXEL analyst consensus is Buy, based on ratings from 32 Wall Street analysts over the past 3 months. The average 12-month price target is $47.33, representing -10.19% downside from the current price of $52.70.
Competitors & Peers
exel competitorsEXEL
ALGN
BBIO
BMRN
CAI
HALOStock Performance
Full HistoryAbout Exelixis, Inc.
Exelixis, Inc. an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products i…
what is exelixis, inc. · exel stock overview · exelixis, inc. company profile · who is exelixis, inc. ceo · exel NASDAQ · exelixis, inc. headquarters · exelixis, inc. business segments
About Stock Overview & Key Data
Exelixis, Inc. (EXEL) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Apr 17, 2000. As of the latest trading session, EXEL stock price is $52.70, with a market capitalization of $13.2B. The stock has returned +22.79% over the past 12 months and +20.24% year-to-date.
According to 32 Wall Street analysts, the consensus rating for Exelixis, Inc. stock is Buy, with an average 12-month price target of $47.33. In fiscal year 2026, Exelixis, Inc. reported revenue of $2.3B and net income of $782.6M. For detailed data — including Exelixis, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Exelixis, Inc. (EXEL) stock price is $52.70. The stock is traded on NASDAQ under the ticker symbol EXEL. The 52-week range is $33.76 – $52.98.